NYSE · CIK 0000885725 · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
BOSTON SCIENTIFIC CORPORATION
BSX chart by TradingView
PRICE HISTORY
LIVE · NYSEBSX chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $20.1B
- EBITDA
- $5.0B
- FREE CASH FLOW
- $3.7B
- EPS
- $1.94
- GROSS MARGIN
- 69.01%
- ROIC
- 12.82%
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
17.2x
-96%10.8x405.4x
⤢
P / SALES (TTM)
3.0x
-23%3.0x8.7x
⤢
P / BOOK
2.5x
-50%2.5x7.2x
⤢
EV / EBITDA (TTM)
11.8x
-72%11.8x47.7x
⤢
EV / REVENUE (TTM)
3.1x
-33%3.1x8.7x
⤢
FCF YIELD (TTM)
5.76%
+3.8pp-0.01%5.76%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$5.4B
+159%⤢
EBITDA (DERIVED)
$1.4B
+156%⤢
NET INCOME
$0.9B
+297%⤢
EPS (DILUTED)
$0.61
+271%⤢
REVENUE GROWTH YOY
7.53%
+4.2pp-23.87%53.62%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
23.50%
+28.3pp-19.16%25.84%
⤢
RETURN ON CAPITAL
14.06%
+13.4pp-0.60%31.18%
⤢
RETURN ON EQUITY (TTM)
14.72%
+13.5pp-0.54%33.87%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN70.71%
OPERATING MARGIN21.65%
NET MARGIN16.63%
FCF MARGIN23.50%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$1.3B
+$1.4B⤢
STOCK-BASED COMP
$0.1B
+200%⤢
CAPITAL EXPENDITURE
$0.2B
+175%⤢
SHARES OUTSTANDING
1.47B
+7%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.5B
+127%⤢
TOTAL DEBT
$1.7B
-68%⤢
DEBT / EBITDA (TTM)
0.3x
-95%0.0x6.1x
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 96.11%INSIDERS 0.25%OTHER / RETAIL 3.64%2,253 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 9.10% | 131.8M | $6.50B | -3.1% |
| Vanguard Capital Management LLC | 6.65% | 96.4M | $4.75B | NEW |
| FMR, LLC | 5.12% | 74.2M | $3.66B | -23.8% |
| State Street Corporation | 4.69% | 68.0M | $3.35B | +3.3% |
| JPMORGAN CHASE & CO | 2.30% | 33.4M | $1.64B | +31.4% |
| Geode Capital Management, LLC | 2.30% | 33.3M | $1.64B | +2.8% |
| Primecap Management Company | 2.24% | 32.5M | $1.60B | +4.6% |
| Vanguard Portfolio Management LLC | 2.06% | 29.8M | $1.47B | NEW |
| Massachusetts Financial Services Co. | 1.72% | 24.9M | $1.23B | +126.1% |
| Shaw D.E. & Co., Inc. | 1.68% | 24.3M | $1.20B | +116.1% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.